Case Report
Accepted on 23 Feb 2026
Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor
in Cancer Molecular Targets and Therapeutics
Case Report
Accepted on 23 Feb 2026
in Cancer Molecular Targets and Therapeutics
Original Research
Accepted on 23 Feb 2026
in Sustainable Consumption
Original Research
Accepted on 23 Feb 2026
in Renal Endocrinology
Editorial
Accepted on 23 Feb 2026
in Exercise Physiology
Case Report
Accepted on 23 Feb 2026
in Neuro-Ophthalmology
Review
Accepted on 23 Feb 2026
in Signaling
Original Research
Accepted on 23 Feb 2026
in Movement Disorders
Original Research
Accepted on 23 Feb 2026
in Data Visualization
Original Research
Accepted on 23 Feb 2026
in Clinical Diabetes
Original Research
Accepted on 23 Feb 2026
in Obstetrics and Gynecology
Original Research
Accepted on 23 Feb 2026
in In Vitro Toxicology
Original Research
Accepted on 23 Feb 2026
in Neurological Biomarkers
Mini Review
Accepted on 23 Feb 2026
in Protein Biochemistry for Basic and Applied Sciences
Original Research
Accepted on 23 Feb 2026
in Autism
Study Protocol
Accepted on 23 Feb 2026
in Political Participation
Original Research
Accepted on 23 Feb 2026
in Sport Psychology